Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Myeloproliferative Disorders 4Primary Myelofibrosis 3Polycythemia Vera 3Leukemia, Myeloid, Acute 2Thrombocytosis 1Thrombocythemia, Essential 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Megakaryoblastic, Acute 1

Interventions

ruxolitinib 4Specimen Handling 3Biopsy 3venetoclax 2trametinib 1sonidegib 1siltuximab 1regorafenib 1ponatinib 1pomalidomide 1pevonedistat 1pertuzumab 1pembrolizumab 1pelcitoclax 1peginterferon alfa-2b 1palbociclib 1olaparib 1neratinib 1luspatercept 1lorlatinib 1lenvatinib 1itacitinib 1imetelstat 1idelalisib 1enzalutamide 1entrectinib 1enasidenib 1durvalumab 1dehydroftorafur 1darolutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thrombocytosis × pomalidomide × Myeloid × Clear all
NCT00946270 2019-06-10

Pomalidomide for Myelofibrosis Patients

M.D. Anderson Cancer Center

Phase 2 Completed
70 enrolled 10 charts
Myeloid

Polycythemia Vera, Thrombocytosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡